Bahija Jallal Husband, Wikipedia, House, Net Worth, Salary, Biography
Bahija Jallal Husband, Wikipedia, House, Net Worth, Salary, Biography -: Bahija Jallal is a remarkable individual who has made significant contributions to the world of biopharmaceuticals and healthcare. In this article, we’ll explore various aspects of her life, from her career achievements to her personal life, house, net worth, and more. Let’s get to know Bahija Jallal in simple, human-friendly language.
Bahija Jallal Bio
|Full Name||Bahija Jallal|
|Date of Birth||May 9, 1965|
|Place of Birth||Morocco|
|Current Position||Independent Director at Guardant Health Inc (since 2019)|
|Net Worth (2023)||Approximately $732,000|
|Residence||505 Penobscot Drive, Redwood City, California, USA|
|Age||58 years old (as of 2023)|
Bahija Jallal Early Life and Education
Bahija Jallal, known for her extensive knowledge in the field of biopharmaceuticals, was born on May 9, 1965. She hails from Morocco but later made her mark in the United States. Her educational journey is equally impressive. She holds a Ph.D. degree in physiology and a DEA degree in physiology and biology from the Université de Paris VI. She also earned an AEA degree in plant physiology and an M.S. degree in biology from the Université de Paris VII.
Bahija Jallal Career Achievements
Dr. Bahija Jallal has had a remarkable career in the pharmaceutical and biopharmaceutical industry. She served as the Executive Vice President of AstraZeneca PLC, a renowned pharmaceutical company, from October 2013 to January 2019. During her tenure, she contributed significantly to the company’s growth.
Moreover, she held the position of President at MedImmune, a subsidiary of AstraZeneca, from January 2013 to January 2019. Her journey with MedImmune began in 2006, where she held various research and development positions. Her dedication and expertise led her to become Senior Vice President of Research and Development from 2010 to 2013.
Bahija Jallal Net Worth and Salary
Bahija Jallal’s estimated net worth stands at a substantial $732,000. She has a significant stake in Guardant Health Inc., with ownership of over 1,814 units of GH stock valued at approximately $267,651. Over the last six years, she has sold GH stock worth over $0. In addition to her stock holdings, she earns an annual salary of $464,522 as an Independent Director at Guardant Health Inc.
Bahija Jallal Personal Life and House
When it comes to Bahija Jallal’s personal life, she is a private individual who prefers to keep her personal matters out of the spotlight. Information about her husband and family is not readily available in the public domain. Her primary focus has been on her career and contributions to the healthcare industry.
As for her residence, her mailing address, as per SEC filings, is listed as 505 Penobscot Drive, Redwood City, San Mateo County, California, 94063, United States. However, specific details about her house are not publicly disclosed.
Bahija Jallal Age and Other Details
Bahija Jallal was born in 1965, making her 58 years old as of 2023. She has been serving as the Independent Director of Guardant Health Inc. since 2019. In terms of her position at Guardant Health Inc., there are five executives older than her and ten executives younger than her. The oldest executive at the company is Stanley Meresman, who is 73 years old and serves as the Independent Director.
Guardant Health Inc
Guardant Health Inc. is a company that believes in tackling cancer as a big data problem. They have developed a comprehensive liquid biopsy, a non-invasive tool for accessing and sequencing tumor DNA. This technology is used by thousands of oncologists to help tens of thousands of advanced cancer patients. Guardant Health Inc. has played a significant role in the acquisition of cancer data, which they believe will lead to important discoveries and new products. The company has secured substantial investments, with backing from investors like Sequoia Capital, Khosla Ventures, OrbiMed, and SoftBank.
Insiders Trading at Guardant Health Inc
Over the last five years, insiders at Guardant Health Inc. have been actively involved in trading the company’s stock. They have traded over $2,653,397,513 worth of Guardant Health Inc. stock and bought 2,436,023 units worth $45,134,604. Notable insiders involved in these trades include Bluebird (Cayman) Ltd Softb…, Bluebird (Cayman) Ltd Svf E…, and Helmy Eltoukhy. On average, Guardant Health Inc. executives and independent directors trade stock approximately every seven days, with the average trade being worth $4,988,526. The most recent stock trade was executed by John G. Saia on September 1, 2023, trading 263 units of GH stock currently worth $9,287.
Bahija Jallal is an accomplished professional with a rich background in biopharmaceuticals and an impressive career at AstraZeneca and MedImmune. While her personal life remains private, her contributions to the healthcare industry and her significant net worth reflect her dedication and success in her field. Guardant Health Inc., the company she is associated with, is actively engaged in innovative approaches to cancer diagnosis and treatment.
Who is the director of Immunocore?
The current director of Immunocore is Dr. Bahija Jallal. She is a physician-scientist with over 20 years of experience in the pharmaceutical industry. She was previously the President of MedImmune, AstraZeneca’s global biologics research and development unit. She is also a member of the Board of Anthem, Inc. and the Board of Trustees of Johns Hopkins University.
What is the salary of Immunocore CEO?
According to the proxy statement filed for the 2021 fiscal year, Bahija Jallal, the CEO of Immunocore, made a total compensation of $3,346,494. This includes $1,225,000 in total cash, $2,076,080 in equity, and $45,414 in pension and other forms of compensation.
What type of company is Immunocore?
Immunocore is a commercial-stage biotechnology company that develops and commercializes a new generation of transformative medicines to address unmet needs in cancer, infectious, and autoimmune diseases. The company’s lead product candidate, tebentafusp (IMCgp100), is currently in Phase 3 clinical trials for the treatment of metastatic uveal melanoma, a rare form of eye cancer. Immunocore also has a robust pipeline of other programs in development for a variety of cancer indications, as well as infectious and autoimmune diseases.
Also Read :